Katharina Mattes

Publications
  1. CD34+ acute myeloid leukemia cells with low levels of reactive oxygen species show increased expression of stemness-genes and can be targeted by the BCL2 inhibitor Venetoclax

    Mattes, K., Gerritsen, M., Folkerts, H., Geugien, M., van den Heuvel, F. A., Flohr Svendsen, A., Yi, G., Martens, J. H. A. & Vellenga, E., 1-Aug-2020, In : Haematologica. 105, 8, p. e399-e403 5 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  2. Transcriptional regulators CITED2 and PU.1 cooperate in maintaining hematopoietic stem cells

    Mattes, K., Geugien, M., Korthuis, P. M., Brouwers-Vos, A. Z., Fehrmann, R. S. N., Todorova, T. I., Steidl, U., Vellenga, E. & Schepers, H., May-2019, In : Experimental Hematology. 73, p. 38-49 12 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  3. CITED2 affects leukemic cell survival by interfering with p53 activation

    Mattes, K., Berger, G., Geugien, M., Vellenga, E. & Schepers, H., 1-Jan-2017, In : Cell death & disease. 8, 10, 10 p., 3132.

    Research output: Contribution to journalArticleAcademicpeer-review

View all (6) »

ID: 13697533